Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma

Carcinoma, Squamous Cell

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.

125mg, oral administration, three times per day.

Icotinib

Wang Yi Na, Dr.

Zhao Qiong, Dr.

This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer.

This study is designed to evaluate the efficacy of icotinib at routine dose in previously treated non/light-smoking patients with advanced squamous cell lung cancer. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, confirmed at least 28 days following the date of the initial response.

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer

Number of participants with an objective response. An objective response (OR) was defined as a patient having a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, confirmed at least 28 days following the date of the initial response.

Progression free survival was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first.

Overall Survival was assessed via calculation of the time to death due to any cause. If a participant was known to have died, the time to death was defined as the time from the date of randomization to the date of death. Otherwise, a participant was censored at the last date they were known to be alive.

Adverse events, serious adverse events, incidence of and reason for study drug dose interruptions and discontinuations, laboratory assessments, vital signs.

Zhejiang University

Prof.

Carcinoma, Non-Small-Cell Lung

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Paclitaxel

Carboplatin

Albumin-Bound Paclitaxel

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Treatment of Albumin paclitaxel plus carboplatin

Treatment of Gemcitabine plus carboplatin

Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.

Albumin paclitaxel plus carboplatin

Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.

Gemcitabine plus carboplatin

Wu Yilong, professor

This trial is to study the efficacy of nab-PC vs. GC and evaluate toxicity of nab-PC in advanced squamous cell cancer of lung. The correlation between the efficacy of nab-PC and some biomarkers is also to be evaluated.

Albumin-bound paclitaxel(nab-P) utilizes the albumin binding proteins,such as (gp60)/caveolin-1 (CAV1) and SPARC(secreted protein acidic and rich in cysteine), achieving high intratumoral paclitaxel accumulation. It is reported that CAV1 is overexpressed in squamous cell cancer(SQC), so it is possible that nab-PC is more highly active than GC in SQC of lung.

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung

ORR is evaluated after at most 6 cycles of chemotherapy, which may cost 18 weeks.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer	NCT02009605	Squamous Cell C...	Icotinib	18 Years - 75 Years	Zhejiang University
Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung	NCT01236716	Carcinoma, Non-...	Albumin paclita... Gemcitabine plu...	18 Years - 85 Years	Chinese Society of Lung Cancer
Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer	NCT02009605	Squamous Cell C...	Icotinib	18 Years - 75 Years	Zhejiang University
Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung	NCT01236716	Carcinoma, Non-...	Albumin paclita... Gemcitabine plu...	18 Years - 85 Years	Chinese Society of Lung Cancer

Spots Global Cancer Trial Database for squamous cell carcinoma of lung